CASI Pharmaceuticals (FRA:ENM) Institutional Ownership : 0.23% (As of Jun. 09, 2024)

View and export this data going back to 2007. Start your Free Trial

What is CASI Pharmaceuticals Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, CASI Pharmaceuticals's institutional ownership is 0.23%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, CASI Pharmaceuticals's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, CASI Pharmaceuticals's Float Percentage Of Total Shares Outstanding is 66.01%.

CASI Pharmaceuticals Institutional Ownership Historical Data

The historical data trend for CASI Pharmaceuticals's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CASI Pharmaceuticals Institutional Ownership Chart

CASI Pharmaceuticals Historical Data

The historical data trend for CASI Pharmaceuticals can be seen below:

	2023-08-31	2023-09-30	2023-10-31	2023-11-30	2023-12-31	2024-01-31	2024-02-29	2024-03-31	2024-04-30	2024-05-31
Institutional Ownership	2.11	1.63	0.37	0.37	0.38	0.37	0.37	0.23	0.23	0.23

CASI Pharmaceuticals Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

CASI Pharmaceuticals (FRA:ENM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CASI Pharmaceuticals Inc (FRA:ENM) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

CASI:USA

Address

9620 Medical Center Drive, Suite 300, Rockville, MD, USA, 20850

Website

https://www.casipharmaceuticals.com

CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing innovative therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA. The company primarily operates in the United States, Canada, China and other parts of the world.

CASI Pharmaceuticals (FRA:ENM) Headlines

No Headlines